CA2642826C - Mapc treatment of brain injuries and diseases - Google Patents

Mapc treatment of brain injuries and diseases Download PDF

Info

Publication number
CA2642826C
CA2642826C CA2642826A CA2642826A CA2642826C CA 2642826 C CA2642826 C CA 2642826C CA 2642826 A CA2642826 A CA 2642826A CA 2642826 A CA2642826 A CA 2642826A CA 2642826 C CA2642826 C CA 2642826C
Authority
CA
Canada
Prior art keywords
cells
brain injury
subject
use according
mapcs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2642826A
Other languages
English (en)
French (fr)
Other versions
CA2642826A1 (en
Inventor
Robert W. Mays
Robert J. Deans
David C. Hess
James E. Carroll
Cesar V. Borlongan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ABT Holding Co
Augusta University Research Institute Inc
Original Assignee
Athersys Inc
Augusta University Research Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athersys Inc, Augusta University Research Institute Inc filed Critical Athersys Inc
Priority to CA3028321A priority Critical patent/CA3028321C/en
Publication of CA2642826A1 publication Critical patent/CA2642826A1/en
Application granted granted Critical
Publication of CA2642826C publication Critical patent/CA2642826C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2642826A 2006-01-23 2007-01-23 Mapc treatment of brain injuries and diseases Active CA2642826C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3028321A CA3028321C (en) 2006-01-23 2007-01-23 Mapc treatment of brain injuries and diseases

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76095106P 2006-01-23 2006-01-23
US60/760,951 2006-01-23
PCT/US2007/001746 WO2007087292A2 (en) 2006-01-23 2007-01-23 Mapc treatment of brain injuries and diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3028321A Division CA3028321C (en) 2006-01-23 2007-01-23 Mapc treatment of brain injuries and diseases

Publications (2)

Publication Number Publication Date
CA2642826A1 CA2642826A1 (en) 2007-08-02
CA2642826C true CA2642826C (en) 2019-01-08

Family

ID=40280746

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2642826A Active CA2642826C (en) 2006-01-23 2007-01-23 Mapc treatment of brain injuries and diseases

Country Status (9)

Country Link
EP (1) EP1981515B1 (enExample)
JP (1) JP5432527B2 (enExample)
AU (1) AU2007208367B2 (enExample)
CA (1) CA2642826C (enExample)
DK (1) DK1981515T3 (enExample)
ES (1) ES2420957T3 (enExample)
NZ (1) NZ570614A (enExample)
PL (1) PL1981515T3 (enExample)
WO (1) WO2007087292A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2471904T3 (en) 2005-12-29 2019-02-18 Celularity Inc Placenta stem cell populations
MX339624B (es) 2008-08-20 2016-06-02 Anthrogenesis Corp Composiciones mejoradas de celulas y metodos para preparar las mismas.
JP5950577B2 (ja) * 2008-08-20 2016-07-13 アンスロジェネシス コーポレーション 単離胎盤細胞を使用した脳卒中の治療
CN107095883A (zh) * 2008-09-04 2017-08-29 Abt控股公司 干细胞预防神经元顶梢枯死的用途
AU2010276201B2 (en) * 2009-07-21 2013-10-17 Healios K.K. Use of stem cells to reduce leukocyte extravasation
SG10201501402UA (en) * 2010-02-25 2015-04-29 Abt Holding Co Modulation of macrophage activation
WO2011106476A1 (en) * 2010-02-25 2011-09-01 Abt Holding Company Modulation of microglia activation
AR093183A1 (es) 2010-12-31 2015-05-27 Anthrogenesis Corp Aumento de la potencia de celulas madre de placenta usando moleculas de arn moduladoras
CN104220081A (zh) 2011-06-01 2014-12-17 人类起源公司 利用胎盘干细胞治疗疼痛
MX2016006270A (es) * 2013-11-15 2016-09-07 Anthrogenesis Corp Composiciones que comprenden células perfundidas de placenta humana, subpoblaciones de las mismas y sus usos.
CN105331583B (zh) * 2015-12-08 2019-01-29 广州医科大学附属第三医院 一种促进人诱导多能干细胞向神经元诱导分化的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4353888A (en) 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
US4744933A (en) 1984-02-15 1988-05-17 Massachusetts Institute Of Technology Process for encapsulation and encapsulated active material system
US4749620A (en) 1984-02-15 1988-06-07 Massachusetts Institute Of Technology Encapsulated active material system
JPH0628570B2 (ja) 1986-02-13 1994-04-20 雪印乳業株式会社 カプセル体の製造方法及び装置
EP0301777A1 (en) 1987-07-28 1989-02-01 Queen's University At Kingston Multiple membrane microencapsulation
US5089272A (en) 1989-03-29 1992-02-18 Snow Brand Milk Products Co., Ltd. Process for producing capsules having a permeability-controllable membrane
US5084350A (en) 1990-02-16 1992-01-28 The Royal Institution For The Advance Of Learning (Mcgill University) Method for encapsulating biologically active material including cells
US5578442A (en) 1992-03-23 1996-11-26 Vivorx, Inc. Graft copolymers of polycationic species and water-soluble polymers, and use therefor
CA2169292C (en) 1993-08-12 2010-11-23 E. Edward Baetge Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
AU1508899A (en) 1997-12-02 1999-06-16 Chong Kun Dang Corporation Pharmaceutical composition comprising cyclosporin solid-state microemulsion
US7015037B1 (en) 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
CA2438501C (en) 2001-02-14 2014-09-16 Leo T. Furcht Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
US9969980B2 (en) * 2001-09-21 2018-05-15 Garnet Biotherapeutics Cell populations which co-express CD49c and CD90
AU2003209259A1 (en) * 2002-01-14 2003-07-30 The Board Of Trustees Of The University Of Illinois Novel mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof
WO2004099395A2 (en) * 2003-05-08 2004-11-18 Cellartis Ab A method for the generation of neural progenitor cells

Also Published As

Publication number Publication date
ES2420957T3 (es) 2013-08-28
NZ570614A (en) 2012-07-27
EP1981515B1 (en) 2013-04-24
AU2007208367B2 (en) 2013-05-16
CA2642826A1 (en) 2007-08-02
WO2007087292A3 (en) 2007-11-22
PL1981515T3 (pl) 2014-02-28
WO2007087292A2 (en) 2007-08-02
EP1981515A2 (en) 2008-10-22
JP5432527B2 (ja) 2014-03-05
JP2009523846A (ja) 2009-06-25
DK1981515T3 (da) 2013-07-22
AU2007208367A1 (en) 2007-08-02

Similar Documents

Publication Publication Date Title
US20210299185A1 (en) Mapc treatment of brain injuries and diseases
CA2642826C (en) Mapc treatment of brain injuries and diseases
US10117900B2 (en) MAPC treatment of brain injuries and diseases
US20220118026A1 (en) Mapc treatment of brain injuries and diseases
HK1224562A1 (en) Mapc treatment of brain injuries and diseases
HK1130695A (en) Mapc treatment of brain injuries and diseases
HK1130694A (en) Mapc therapeutics without adjunctive immunosuppressive treatment

Legal Events

Date Code Title Description
EEER Examination request